



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/887,541	06/21/2001	Thomas J. Brennan	R-17

CONFIRMATION NO. 5815

FORMALITIES LETTER



OC000000007683155

DeltaGen., Inc.
740 Bay Road
Redwood City, CA 94063

Date Mailed: 03/21/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 3 - OFFICE COPY

0300
#7

Mike

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Application of:

Thomas J. BRENNAN et al

Serial No.: 09/887,541

Filed: June 21, 2001

For: Transgenic Mice Containing PAFR
Gene Disruptions



Docket No.: R-17

Group Art Unit: 1619

Examiner: Unassigned

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed March 21, 2002 regarding the above-captioned application, Applicants submit herewith:

1. A sequence listing in paper and computer readable form pursuant to 37 C.F.R. §1.821(c) and (e); and
2. A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

The content of the paper and computer readable copies of the sequence listing submitted in this application are the same. Moreover, as the sequence listing merely presents nucleotide and/or amino acid sequences that appeared in the application as originally filed in accordance with 37 C.F.R. §1.821-1.825, no new matter has been introduced into the application.

Accordingly, Applicants respectfully request the entry of the paper and computer readable forms of the sequence listing into the application.

Date: May 20, 2002

Respectfully submitted,


Robert J. Driscoll, Reg. No. 47,536

Deltagen, Inc.
740 Bay Road
Redwood City, CA 94063
(650) 569-5100

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Thomas J. BRENNAN et al.

Docket No.

R-17

Serial No.

09/887,541

Filing Date

June 21, 2001

Examiner


Unassigned

Group Art Unit

1619

Invention:

TRANSGENIC MICE CONTAINING PAFR GENE DISRUPTIONS



RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
I hereby certify that this CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES
(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: ~~The~~
U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
~~Commissioner of Patents and Trademarks, Washington, D.C. 20231-0001~~ on May 20, 2002
(Date)

Deborah A. Mojarro

(Typed or Printed Name of Person Mailing Correspondence)

A handwritten signature in cursive script, appearing to read "Deborah A. Mojarro".

(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.